Myelofibrosis Market Positioned for Substantial Expansion, Driven by FDA Designations and Promising Clinical Results | DelveInsight

The myelofibrosis treatment market is anticipated to witness robust expansion owing to the introduction of investigational therapies by key participants including AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, Ns Pharma, Galecto Biotech, Actuate Therapeutics, Merck, Menarini Group, Telios Pharma, Disc Medicine, Syntara, Sumitomo Pharma, and Incyte, among others, which are advancing myelofibrosis research to address unmet requirements.

DelveInsight's "Myelofibrosis Market Insight, Epidemiology And Market Forecast – 2034" document delivers comprehensive understanding of Myelofibrosis, historical and projected epidemiology, alongside the Myelofibrosis market dynamics in the 7MM which encompass the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The myelofibrosis market valuation, assessed at USD 2.2 billion in 2024, is projected to expand at a rapid CAGR over the forecasted period (2025–2034). This expansion is fueled by rising myelofibrosis prevalence, enhanced diagnostic capabilities, and the introduction of innovative therapies targeting diverse patient subgroups. Among the 7MM, the US captured the largest market proportion with USD 1,700 million in 2024. Furthermore, among all therapies, JAKAFI/JAKAVI (ruxolitinib) represented the largest myelofibrosis market valuation in 2024, with USD 1.5 billion.

Download the myelofibrosis market report to understand which factors are driving the myelofibrosis market @ myelofibrosis Market Trends.

The document delivers comprehensive epidemiological analysis and forecasts extending to 2034. This analysis is categorized by total myelofibrosis prevalent cases, type-specific cases, myelofibrosis cases based on risk stratification, age-specific myelofibrosis cases, and myelofibrosis cases based on molecular alterations in the 7MM.

According to DelveInsight's analysis, the total myelofibrosis prevalence in the 7MM was nearly 56K in 2024. High-risk myelofibrosis represented the largest patient population in the US, with primary myelofibrosis constituting approximately 75% of all cases. This trend is anticipated to continue in the forecasted period (2025–2034).

For most individuals with myelofibrosis, management remains aimed at controlling disease symptoms and complications, enhancing quality of life, and extending survival. Key marketed therapies encompass JAKAFI (ruxolitinib) and INREBIC (fedratinib), which have dominated the environment as JAK inhibitors provide unprecedented benefits to myelofibrosis individuals in terms of spleen shrinkage and symptom improvement. However, the patent for JAKAFI is anticipated to expire in 2027 for Novartis and in 2028 for Incyte, opening up opportunities for investigational therapies.

As JAK inhibitor therapy is associated with certain complications, new treatments for myelofibrosis are focusing on mechanisms beyond JAK inhibitors. These encompass imetelstat (telomerase inhibitor), navtemadlin (MDM2 protein inhibitor), pelabresib (BET inhibitor), among others that may meet the patient's requirements and provide an alternative myelofibrosis treatment.

According to DelveInsight's analysis, the myelofibrosis competitive environment is further enriched by several organizations initiating clinical investigations for new options. The pipeline encompasses drugs including BESREMi (PharmaEssentia and AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb and Merck), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), Bomedemstat (Merck), TL-895 (Telios Pharma), RVU120 (Ryvu Therapeutics), TP-3654 (Sumitomo Pharma), SNT-5505 (Syntara), DISC-0974 (Disc Medicine), and ELZONRIS (Menarini Group), among others.

Discover evolving trends in the myelofibrosis treatment landscape @ myelofibrosis therapies.

Beyond JAKAFI and INREBIC, the current myelofibrosis treatment environment also encompasses approved drugs like VONJO (CTI BioPharma), a JAK2/IRAK1 inhibitor, approved in 2022 for managing adults with intermediate or high-risk primary or secondary myelofibrosis. OJJAARA (GSK), a JAK1/2 and ACVR1 inhibitor targeting anemia, which represents the only approved agent for both newly diagnosed and previously managed individuals with myelofibrosis and anemia, was approved in 2023. Omjjara's unique mechanism addressing hepcidin dysregulation positions it to reshape the secondary myelofibrosis treatment market, particularly for anemic individuals who face limited options.

Unlock which myelofibrosis investigational drug is expected to capture the largest market share in 7MM by 2034. Visit the Myelofibrosis Market Insights.

The myelofibrosis treatment clinical investigation pipeline is currently active, with notable recent breakthroughs. In January 2025, the BOREAS phase 3 investigation demonstrated that navtemadlin, an MDM2 inhibitor, offers clinical benefits as a single agent in JAK inhibitor–refractory myelofibrosis, demonstrating durable spleen volume reductions and symptom improvements. In March 2025, a Phase 3 investigation demonstrated that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone in managing myelofibrosis, with significant spleen shrinkage and no substantial increase in side effects. These recent findings indicate a strong upward trend in the myelofibrosis treatment market.

In May 2025, the FDA approved belzutifan for adult and pediatric individuals aged 12 years and older with von Hippel-Lindau disease–associated tumors, encompassing myelofibrosis-associated lesions.

In June 2025, Syntara Limited reported FDA Fast Track designation for SNT-5505, targeting myelofibrosis individuals with inadequate response to JAK inhibitors. This designation enables more frequent FDA interactions and eligibility for accelerated approval pathways.

Karyopharm's Phase 3 SENTRY investigation in JAK inhibitor–naïve myelofibrosis passed its futility analysis in May 2025. Full enrollment of 350 individuals is anticipated by July 2025, with top-line results anticipated in late 2025/early 2026.

Despite these advancements, challenges persist. Long-term JAK inhibitor use is associated with cytopenias and infections, while high treatment costs and accessibility barriers limit global reach. DelveInsight's analysis emphasizes the requirement for cost-effective therapies and personalized approaches leveraging genetic profiling.

Looking ahead, the myelofibrosis treatment market is positioned for diversification with a robust developmental pipeline, encompassing BET inhibitors, PI3K inhibitors, and immunomodulators. The integration of biomarkers and combination regimens is anticipated to enhance response durability and address resistance.

Key Insights
Report Introduction
Executive Summary Of Myelofibrosis
Myelofibrosis Epidemiology And Market Methodology
Key Events
Myelofibrosis Market Overview At A Glance
Myelofibrosis Background And Overview
Myelofibrosis Treatment And Management
Myelofibrosis Treatment Guidelines
Myelofibrosis Epidemiology And Patient Population
Myelofibrosis Patient Journey
Myelofibrosis Clinical Trials Key Endpoints
Myelofibrosis Marketed Drugs
Myelofibrosis Emerging Therapies
Myelofibrosis Market Analysis (7MM)
Market Access And Reimbursement
SWOT Analysis
Myelofibrosis Unmet Needs
KOL Views
Appendix
Delveinsight Capabilities
Disclaimer
About Delveinsight

Related Report

Myelofibrosis Pipeline Insight

Myelofibrosis Pipeline Insight delivers comprehensive intelligence about the Myelofibrosis pipeline environment, pipeline drug profiles, encompassing clinical and non-clinical stage products, and the Myelofibrosis organizations, including Geron Corporation, Merck, Telios Pharma, Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, and Sumitomo Pharma America, Inc., among others.

About DelveInsight

DelveInsight represents a leading market research and consulting organization specializing in disease-specific insights and therapeutic market analysis. Their documents integrate real-world data, clinical investigation findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Mehul Malhotra

Email: [email protected]

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/